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Abstract
Hepatocellular carcinoma (HCC) remains a major problem in oncology. The molecular mechanisms which underlie its
pathogenesis are poorly understood. Recently the Small Heterodimer Partner (SHP), an orphan nuclear receptor, was
suggested to be involved as a tumor suppressor in hepatocellular carcinoma development. To date, there are no such
studies regarding fibrolamellar carcinoma, a less common variant of HCC, which usually affects young people and displays
distinct morphological features. The aim of our project was to evaluate the SHP levels in typical and fibrolamellar
hepatocellular carcinoma with respect to the levels of one of the cell cycle regulators, cyclin D1. We assessed the
immunoreactivity levels of SHP and cyclin D1 in 48 typical hepatocellular carcinomas, 9 tumors representing the
fibrolamellar variant, 29 non malignant liver tissues and 7 macroregenerative nodules. We detected significantly lower SHP
immunoreactivity in hepatocellular carcinoma when compared to non malignant liver tissue. Moreover, we found that SHP
immunoreactivity is reduced in fibrolamellar carcinoma when compared to typical hepatocellular carcinoma. We also found
that SHP is more commonly lost in HCC which arises in the liver with steatosis. The comparison between the cyclin D1 and
SHP expression revealed the negative correlation between these proteins in the high grade HCC. Our results indicate that
the impact of loss of SHP protein may be even more pronounced in fibrolamellar carcinoma than in a typical form of HCC.
Further investigation of mechanisms through which the loss of SHP function may influence HCC formation may provide
important information in order to design more effective HCC therapy.
Citation: Wilczek E, Szparecki G, Lukasik D, Koperski L, Winiarska M, et al. (2012) Loss of the Orphan Nuclear Receptor SHP Is More Pronounced in Fibrolamellar
Carcinoma than in Typical Hepatocellular Carcinoma. PLoS ONE 7(1): e30944. doi:10.1371/journal.pone.0030944
Editor: Joerg F. Schlaak, University Hospital of Essen, Germany
Received August 24, 2011; Accepted December 27, 2011; Published January 23, 2012
Copyright:  2012 Wilczek et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: The presented work was supported by the grant no 3509/B/P01/2010/38 from the Polish State Committee for Scientific Research. Contributing author
M.W. is a member of TEAM Programme co-financed by the Foundation for Polish Science and the EU European Regional Development Fund, and is supported by
grants from the Ministry of Science and Higher Education of Poland: N N402 352938 (M.W.) and ’’Iuventus Plus’’ 0465/P01/2010/70. The funders had no role in
study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: ewa.wilczek@wum.edu.pl
Introduction
Hepatocellular carcinoma (HCC) represents the most common
primary malignant liver tumor. It affects approximately 700 000
people annually [1]. In spite of significant progress in the last few
decades in understanding cancer biology, the comprehensive
HCC pathogenesis still remains not fully understood. To date,
there are no specific biomarkers with potent diagnostic and
prognostic significance for HCC treatment. In part it ensues from
diverse etiologic factors and liver disorders, on basis of which HCC
usually arises. The major risk factors for HCC development are
hepatitis B and hepatitis C infection, exposure to aflatoxins and
disorders which proceed with liver cirrhosis [2]. So far, surgical
resection remains the most effective treatment; however, there still
remains a cohort of patients to which this type of cure cannot be
applied. In the field of targeted therapy a multikinase inhibitor,
sorafenib showed modest survival benefits in patients with
advanced HCC [3]. Fibrolamellar carcinoma (FL) represents a
variant of hepatocellular carcinoma which typically arises without
viral infection or cirrhosis. It usually affects young people and it is
known to have better prognosis and more favorable outcome when
compared to conventional hepatocellular carcinoma. Histologi-
cally FL exhibits distinct morphological pattern from classic HCC
with typical large polygonal cells surrounded with lamellar bands
of collagen. Tumor cells possess granular eosinophilic cytoplasm
with prominent nucleoli. Since fibrolamellar carcinoma represents
rather rare variant of HCC, it was a subject of a limited number of
study and little is known about the molecular events involved in its
pathogenesis.
Nuclear receptors (NR) represent a broad family of proteins
with known function as transcription factors which regulate gene
expression after binding specific ligands. NR bind to promoter
sequences of target genes through the DNA - binding domain
(DBD) upon ligand stimulation. Currently, emerging data indicate
that nuclear receptors may play an important role in cancer
development. To date, the function of the nuclear receptors in
carcinogenesis was documented for members of both endocrine
(estrogen, androgen, Vitamin D, thyroid hormone, progesterone)
and orphan (peroxisome-proliferator-activated receptors and
retinoid acid) subfamilies [4]. The small heterodimer partner
PLoS ONE | www.plosone.org 1 January 2012 | Volume 7 | Issue 1 | e30944(SHP, NROB2) belongs to the family of the so-called orphan
nuclear receptors, to which no ligand is currently known [5]. SHP
protein does not have typical nuclear receptor structure since it is
unable to bind DNA due to the lack of the DBD. Its transcription
regulation activity is accomplished by altering function of other
nuclear receptors via ligand binding domain (LBD), localized at
the C-terminus. It acts usually by repressing transcriptional activity
of approximately half of all mammalian nuclear receptors [6].
SHP function was primarily linked to cholesterol metabolism and
glucose homeostasis, since the lack of functional SHP has been
coupled with cholestasis, diabetes and obesity [6]. More recent
data revealed that SHP may function as a tumor suppressor
playing role in cancer pathogenesis. It was found that SHP may
function by inhibiting tumor growth and inducing apoptosis
through regulation of mitochondria in peritoneal pancreatic
cancer cells [7].
Cyclin D1 is one of the key regulators of cell cycle progression,
which allows cell to pass through the G1 phase. Frequently, during
cancer development the increase in cell proliferation rate is
associated with overexpression of the cyclin D1 as a result of
chromosomal translocation or gene amplification [8]. However, in
many malignancies the increased levels of cyclin D1 protein
proceeds without obvious gene rearrangements. In those cases the
possible cause may be the deregulation of protein degradation or
Figure 1. SHP immunoreactivity in normal liver. A, B – immunohistochemical staining of the normal hepatic lobule; C, D- immunofluorescence
staining showing exclusively nuclear (C) or cytoplasmic (D) SHP localization in different lobules; scale bar: A 100 mm; B 20 mm; C,D 25 mm. E- result of
the SHP immunohistochemistry preceded with (lower image) or without (upper image) anti-SHP blocking antibody; F- Western blot analysis of three
liver (LV1–LV3) lysates, the SHP protein present in a single band; G- Result of the RT-PCR study showing the SHP mRNA in the normal liver; GAPDH
mRNA was used as a control.
doi:10.1371/journal.pone.0030944.g001
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Zhang et al., cyclin D1 was found to be negatively regulated by the
orphan nuclear receptor SHP thus influencing cellular prolifera-
tion [8]. They found enhanced hepatocyte proliferation and
increased cyclin D1 expression in SHP knockout mice which
resulted in tumorigenesis and spontaneous tumor formation.
To date, there are no studies showing the SHP levels in different
subtypes, i.e., fibrolamellar variant of HCC, as well as there are no
correlation studies between the expression of SHP and cyclin D1
in human liver cancer. In a present study we performed a
comprehensive immunohistochemical study of the SHP levels in
hepatocellular carcinoma. Additionally, we performed a compar-
ison study between the expression of the small heterodimer partner
and the key cell cycle regulator, cyclin D1, in different
morphological variants of HCC and according to tumors grading.
Results
The presence and intensity of the SHP immunoreactivity
in normal hepatocytes depends on its localization within
the liver lobule
The immunohistochemical staining of hepatic lobules revealed
gradual pattern of SHP immunoreactivity, being the most intensive
in the zone around central vein (centrolobular zone) and less
prominent in a zone around portal tract (perilobular zone; Fig. 1A).
Very commonly there was variable staining of hepatocytes within
one lobule, such that strongly- and weakly-immunoreactive
hepatocytes were juxtaposed (Fig. 1B). As was revealed by detailed
immunofluorescence studies, the localization of SHP immunoreac-
tivity was cytoplasmic in the majority of hepatocytes, less prominent
wasnuclear staining.Withinthe samelobuletherewerehepatocytes
with exclusively nuclear (Fig. 1C) or cytoplasmic (Fig. 1D) staining.
The control sections in which rabbit immunoglobulins were used
instead of the primary antibody displayed no immunoreactivity
(data not shown). The immunostaining performed after incubation
with the blocking peptide resulted in no immunopositive structures
in the liver tissue (Fig. 1E). The Western blot analysis of the anti-
SHP antibody, performed on three liver lysates showed a single
band reflecting SHP protein in each sample (Fig. 1F). The RT-PCR
studyon thenormalliver cDNA showed a product correspondingto
SHP mRNA (Fig. 1G).
SHP immunoreactivity is increased in macroregenerative
nodules in cirrhotic liver when compared to the normal
liver
Hepatocytes in macroregenerative nodules displayed strong,
uniform cytoplasmic SHP immunoreactivity (Fig. 2A, B). In all
such tissue samples 100% of cells were positive for SHP staining,
with strong to moderate staining intensity. The range of the SHP
total score was from 207 to 300, with the medium level of 254
arbitrary units.
SHP immunoreactivity is significantly decreased in
hepatocellular carcinoma
The patient clinical data and SHP immunoreactivity presented
in arbitrary units as a total score are demonstrated in Table 1. The
medium SHP total score level for the control group was 166.
Compared to the normal liver, hepatocellular carcinoma samples
displayed decreased SHP immunoreactivity, although there was
some diversity among cases. About 5% of examined tumors
displayed strong immunoreactivity present in virtually all cancer
cells (Fig. 3A). In the rest of cases, heterogeneous staining of cancer
cells within one sample was most frequently seen, namely SHP-
positive tumor cells were often surrounded by cancer cells without
SHP immunoreactivity (Fig. 3B). In a border zone between
positive and negative tumor cells, intermediately stained cells were
seen. There was a small subgroup of tumor samples (5%), with
strong SHP immunoreactivity present only in few apoptotic-like
cells (Fig. 3C). In 26% of tumors we did not detect any SHP
immunoreactivity (Fig. 3D). We found that the level of the SHP
negatively correlated with the AFP value (p=0,048; with
correlation coefficient 20.45; Spearman’s rank test). We did not
detect statistically significant differences in SHP immunoreactivity
depending on differentiation grade. The intracellular pattern of
SHP immunoreactivity was similar to which was found in the
normal liver. Statistical analysis revealed significantly reduced
SHP immunoreactivity in HCC group when compared to the
normal liver (p=0,00401; Mann-Whitney test, Fig. 3F).
Fibrolamellar variant of HCC displays significantly less
SHP immunoreactivity than a typical HCC
In our group of hepatocellular carcinoma we had 9 cases of
fibrolamellar variant of HCC. In this subgroup we found 7 (78%)
tumors that were completely negative for SHP immunoreactivity
or had less than 5% of positive cells. In two tumors, there were
SHP positive cells present. Taking into account total score of
immunopositive cells we found that in a fibrolamellar variant of
HCC there was significantly less SHP immunoreactivity, when
compared to typical HCC (p=0,021; Mann-Whitney test; Fig. 3F).
The immunoreactivity of cyclin D1 negatively correlates
with the presence of the nuclear receptor SHP in the
high grade typical hepatocellular carcinoma
The cyclin D1 immunoreactivity was detected in the majority of
tumors, although to a variable degree (Fig. 4A). We detected cyclin
Figure 2. SHP immunoreactivity in macroregenerative nodules. Note uniform staining of all hepatocytes; scale bar A-100 mm, B-50 mm.
doi:10.1371/journal.pone.0030944.g002
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Sex Age Ca cm Inflamm G S Concomitant disease AFP ng/ml Tissue SHP CD1
1. F 40 18 2 2 1 none * HCC 0 71
2. F 46 9 0 2 2 none * HCC 0 1
3. M 62 5 1 2 2 HCV, C N HCC 0 45,5
4. F 57 7 1 3 2 none 7001 HCC 0 10
5. M 27 5 0 2 1 HBV, C * HCC 0 18
6. M 57 15 2 2 3 HBV,C, R * HCC 0 138,5
7. M 44 9,5 2 2 1 none * HCC 0 13
8. M 76 4 3 3 1 HCV, C N HCC 0 55
9. M 67 6 2 3 2 HBV, C 2926 HCC 0 7
10. F 68 5,5 2 3 1 HCV, C 1013 HCC 0 0
11. M 23 19 1 n/a 3 none 73,4 FL 0 0
12. M 57 15 0 2 3 HCV, C 803 HCC 0 0
13. F 28 14 0 n/a 3 none N FL 0 68
14. M 23 16 0 n/a 1 none * FL 0 0
15. F 48 7,5 1 n/a 2 breast ca * FL 0 4
16. M 47 4 0 n/a 1 none * FL 0 0,5
17. M 70 7 0 3 2 C, R N HCC 1,5 0,5
18. M 62 4,5 2 3 2 HCV * HCC 4 99
19. F 28 15 0 2 2 none * HCC 5 0
20. F 24 * 0 n/a 3 R * FL 12 61
21. M 55 7 2 3 2 HCV, C 115,7 HCC 10 70,5
22. F 24 17 0 n/a 2 none * FL 13 48,5
23. F 75 5,5 0 3 2 HBV 3665 HCC 16 59
24. M 55 15 0 2 3 HBV 100,8 HCC 27 89,5
25. F 23 15 0 n/a 1 none * FL 40 18
26. F 68 8,5 3 3 2 C 100,7 HCC 56 2
27. M 47 15 0 3 2 none 35,3 HCC 53 4
28. M 21 14 2 2 2 HBV,C,lymphoma 17500 HCC 33 14
29. M 73 4,5 2 2 1 HBV, C N HCC 68 3,5
30. M 60 4 2 1 1 HCV, C 19,03 HCC 62 69,5
31. M 72 10 1 2 2 C N HCC 55 5
32. M 64 4 1 3 3 C 7596 HCC 63 70
33. M 71 6 0 2 1 larynx ca 68,33 HCC 81 32,5
34. F 52 1,2 1 1 2 HCV, C * HCC 45 0
35. M 57 7 0 2 2 larynx ca N HCC 92 3,5
36. M 61 4,5 0 2 1 HBV, C N HCC 80 3,5
37. F 67 14 1 2 3 none * HCC 134 1
38. F 48 9 1 2 2 HCV * HCC 108 71,5
39. M 71 3,5 1 2 1 HCV, C N HCC 135 24
40. M 60 6 0 2 2 HCV, C N HCC 136 40,5
41. M 69 8,5 3 3 3 none 24,1 HCC 137 9,5
42. M 55 16 0 2 1 none N HCC 145 6
43. F 18 * * n/a * none N FL 155 9,5
44. F 62 6 3 3 1 none 448,8 HCC 137 0
45. M 42 5 2 2 1 C * HCC 240 30,5
46. F 71 3,5 0 3 1 HCV, R ,C 51,06 HCC 184 16
47. M 75 13 0 2 2 none 612 HCC 235 46,5
48. M 63 5,5 3 2 1 none N HCC 278 28
49. M 42 10 0 2 1 HCV, C * HCC 189 6
50. F 58 8 0 2 2 HCV, C 122,7 HCC 180 7
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noma, usually considered as a slowly proliferating type of cancer
(Fig. 4B). The correlation analysis revealed that in the high grade
typical hepatocellular carcinoma there was a negative correlation
between the immunoreactivity of SHP and cyclin D1 (p=0,0096;
the correlation coefficient 20,59; Spearman’s rank test Fig. 4 C).
Interestingly, in FL HCC group we did not find such correlation.
Discussion
In our study we report that the nuclear receptor SHP expression
is reduced in hepatocellular carcinoma tissue when compared to
normal liver. We present for the first time that fibrolamellar
carcinoma contains less SHP protein than typical hepatocellular
carcinoma. Finally, we demonstrate a negative correlation
between the expression of SHP and one of the most potent cell
cycle regulator, cyclin D1, in high grade hepatocellular carcino-
mas. Together our studies are consistent with hypothesis that
reduced SHP expression may play a significant role in hepatocel-
lular and fibrolamellar carcinoma development.
The involvement of nuclear receptors signaling in cancer
pathogenesis was documented in prostate, breast, colon and lung
cancer [9,10,11,12]. In typical nuclear receptors the mechanism
by which NR exert their function is direct binding to specific genes
which control cell proliferation and survival. Since SHP does not
possess DNA binding domain, it inhibits transcription process
acting as a corepressor or coactivator competitor by direct binding
to other nuclear proteins [6]. The role of SHP as a tumor
suppressor in hepatocellular carcinoma was recently postulated in
a work of He et al. [13]. The authors show that diminished SHP
expression results from epigenetic inhibition of protein expression.
In our study we found SHP localized mainly in the cytoplasm of
both normal and malignant hepatocytes. For nuclear receptors
that have known ligands, the cytoplasmic localization usually
reflects a state when nuclear receptor is inactive. For example,
androgen receptor, in a basal state is found mainly in the
cytoplasm of prostate epithelial cells. Only after binding to
androgen, AR translocates to the nucleus, where it acts by
affecting transcription of target genes [9]. However, it appears that
the Small Heterodimer Partner may function differently. It can
sequester other nuclear receptors or corepressors in the cytoplasm,
thus preventing interaction with their target genes. For example, in
a work of Kim et al., it was found that SHP can act as a repressor
of Gli1, an effector of Hedgehog signaling pathway having a key
role in hepatocellular carcinoma development [14]. The nuclear
translocation and transcriptional activity of Gli1 is suppressed by
the protein-protein interaction with SHP in the cytoplasm.
Similar mechanism of action was documented in a study
concerning another orphan nuclear receptor, Nurr1 in a bladder
cancer. Inamoto et al. found a positive correlation between the
cytoplasmic localization of this receptor and clinicopathologic
features [15]. The cytoplasmic dominance in expression of Nurr1
over nuclear localization was more common for cancers with
advanced pathologic stage and higher tumor grade.
Other cytoplasmic function of SHP can be targeting cell death
through mitochondrial apoptosis [7]. As was shown by Zhang et
al., SHP upon induction by the synthetic retinoid c receptor
agonist, AHPN (6-[3-(1-adamantyl)-4-hydroxyphenyl]-2-naphtha-
lene carboxylic acid) can be translocated from the nucleus into
mitochondria, when it interacts with Bcl-2 protein, followed by
disruption of the Bcl-2/Bid interaction and cytochrome c release
in cancer cells. Furthermore, even with the absence of the
apoptotic stimuli, overexpression of the SHP protein can trigger
cellular apoptosis via mitochondria. However, in our study we did
not observe the SHP localization in mitochondria, as was revealed
by double immunofluorescence staining of the SHP and
cytochrome oxydase (data not shown) which may reflect distinct
mode of the SHP action in hepatocellular carcinoma.
Fibrolamellar carcinoma is considered less aggressive than a
typical hepatocellular carcinoma. However, the majority of
hepatocellular carcinoma arises in cirrhotic liver, which represents
a strong adverse prognostic feature. Hence, the outcome in HCC
could be distorted by the cirrhosis or other underlying liver disease.
What is more, typical HCC, as opposed to FL, usually develops in
older people, which can also represent less favorable prognostic
factor. Thus, the more favorable outcome in FL can be a result of
the overall characteristic of FL patients rather than the cellular
phenotype of cancer cells. Indeed, in a study of Kakar et al., no
statistical significance in 5-year survival rate of resected fibrolamel-
lar carcinoma was found when compared to hepatocellular
carcinoma in noncirrhotic liver [16]. Additionally, concomitant
studies revealed high frequency of recurrence and resistance to
chemotherapy and radiation therapy in patients with fibrolamellar
carcinoma [17]. The statistically significant lower SHP immunore-
activity in FL when compared to HCC may reflect an important
role of this nuclear receptor in pathogenesis of this particular type of
cancer. In current studies we did not find any negative correlation
between the expression level of SHP and cyclin D1 in fibrolamellar
carcinoma, which may suggest additional mode of action of SHP on
hepatocarcinogenesis other than regulation of the cell cycle through
this particular cell cycle regulator.
In a macroregenerative nodules we found very strong SHP
immunoreactivity which was present in virtually all hepatocytes.
These structures represent a state in the liver where active tissue
Sex Age Ca cm Inflamm G S Concomitant disease AFP ng/ml Tissue SHP CD1
51. M 46 5 2 2 2 HCV, C 92,95 HCC 266 170
52. M 72 11 3 2 2 C * HCC 110 0,5
53. F 54 10 0 2 1 none 475,3 HCC 300 3,5
54. F 62 3,5 2 2 1 C * HCC 300 3
55. M 73 5,5 1 3 2 HCV, C 57,6 HCC 300 1,5
56. M 56 7 0 3 1 none * HCC 300 4,5
57. M 62 4,5 3 3 2 HBV, C 296 HCC 160 7,5
Abbreviations: Ca cm maximal tumor size in cm; Inflamm inflammation; G tumor grade; S stage; N normal; C cirrhosis; R HCC recurrence;
*data not available; n/a not applicable.
doi:10.1371/journal.pone.0030944.t001
Table 1. Cont.
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PLoS ONE | www.plosone.org 5 January 2012 | Volume 7 | Issue 1 | e30944Figure 3. SHP immunoreactivity (SHP IR) in hepatocellular carcinoma. A- strong immunoreactivity; B- partly positive tumor, insert- cells
displaying both cytoplasmic and nuclear staining; C- tumor sample with single positive cells, insert- two apoptotic-like cells displaying SHP
immunoreactivity; D- tumor cells completely negative for SHP immunoreactivity; scale bar A–D 100 mm, insert in B, C- 20 mm; E- categorized
histogram of SHP immunoreactivity in the normal liver, HCC and FL; on the axis of ordinates number of observations was displayed, the axis of
abscissa reflects SHP IR displayed in arbitrary units; color curves show the normalized frequency distribution of SHP IR, F- a graph representing mean
values of SHP IR in FL, HCC and normal liver.
doi:10.1371/journal.pone.0030944.g003
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in regenerative nodules SHP plays a pivotal role. Recent systems-
level gene expression analysis done by Park et al. identified a set of
cell cycle genes regulated by SHP [18]. Moreover, SHP is required
for proper function of many other nuclear receptors acting as a
transcription coregulator. Thus, the abundant presence of SHP in
regenerative liver can represent an autoinhibitory mechanism
which prevents from excessive proliferation of hepatocytes.
In a work of Zhang et al. it was demonstrated that knockout of
SHP gene in mice resulted in spontaneous HCC formation as a
consequence of massive hepatocytes proliferation. This increase in
proliferation rate coincided with cyclin D1 upregulation. Howev-
er, in our work we found such a correlation only in high grade
hepatocellular carcinomas. Possibly the loss of SHP expression
may affect abnormal hepatocyte proliferation when additional
requirements, e.g., present in an dedifferentiated hepatocellular
carcinoma, are met. Therefore, the consequences of loss of SHP
expression and its implication in hepatocarcinogenesis in well
differentiated tumors need to be established.
In summary, our results indicate that the loss of SHP
immunoreactivity is a commonly observed change during hepato-
cellular carcinoma development, and is even more pronounced in
the fibrolamellar one. The unveiling of the mechanisms of such a
loss will potentially have clinical implications.
Materials and Methods
Ethics statement
According to the regulations of our University authorities, a
non-invasive studies, performed on the archival tissue samples do
not require an approval of the Ethics Committee (Art.37 Off.2001,
nr 126, pos. 1382).
Tissue specimens
Tissue samples were obtained from 57 patients, 21 females and
36 males with diagnosed hepatocellular carcinoma. An age range
was from 18 to 76 years, with medium age 54 years. In this group
there were 9 tumors representing fibrolamellar variant of HCC. In
the group of typical HCC (with FL exclusion), 18 tumor samples
represented high grade HCC (G3), 29 were classified as
moderately differentiated (G2) and only one tumor specimen
was classified as well differentiated (G1). As a control group 29
specimens of non malignant liver tissues were included. Among
this group, there were 15 females and 14 males, with an age
ranging from 21 to 76, and medium age 49 years. Additionally, 7
tissue samples with macroregenerative nodules representing
cirrhotic liver were examined. In this group there were 2 females
and 3 males, with medium age 50 years.
Immunohistochemistry/Immunofluorescence
Four micrometer-thick formalin fixed paraffin embedded
sections were deparaffinized in xylene and alcohols. Then the
antigen retrieval in citric buffer was performed in a microwave
oven. The endogenous peroxidase was blocked by incubation with
3% hydrogen peroxide for 30 minutes. After this step sections
were placed in 5% normal horse serum (NHS, Jackson
Immunoresearch, USA), in order to reduce unspecific binding of
the antibody. The anti-SHP (Novus Biologicals, USA; MBL
International, USA) antibody was applied diluted 1:200 in 5%
NHS and kept at 4uC overnight. The detection was performed
with horse anti-rabbit ImmPress Detection Kit (Vector Labora-
tories, USA) and 3, 39-diaminobenzidine (DakoCytomation,
Denmark) as a chromogen. As a control immunoreaction, SHP
antibody, pre-incubated with specific SHP peptide (MBL Inter-
national, USA) with a 406 molar excess of the peptide prior to
application into tissue was used. The cyclin D1 immunoreactivity
was determined with rabbit anti-cyclin D1 antibody (DakoCyto-
mation, Denmark) at a concentration 0,6 mg/ml followed by the
horse anti-rabbit ImmPress secondary antibody, TSA
TM Biotin
Tyramide solution (Perkin Elmer, USA), ABC Vectastain solution
(Vector, USA) and 3,39-diaminobenzidine as a chromogen. For
indirect immunofluorescence analyses sections were pretreated as
for light microscopy, with donkey anti-rabbit–Alexa555 (Jackson
Immunoreseach, USA) secondary antibody used for primary
antibody detection. After immunoreaction sections were counter-
Figure 4. The cyclin D1 expression in hepatocellular carcinoma.
A- the immunoreactivity of cyclin D1 in HCC tumor; B- the cyclin D1
immunoreactivity in fibrolamellar carcinoma; scale bar 5 mm; C-
Spearman’s rank graph showing a negative correlation between the
SHP and cyclin D1 immunoreactivity in G3 hepatocellular carcinoma.
doi:10.1371/journal.pone.0030944.g004
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Laboratories, USA) and analysed under Leica TCS SP5 confocal
microscope (Leica Microsystems, Germany).
Western blot
To assess anti-SHP antibody specifity we performed Western
blot analysis on three lysates from normal liver sections.
Membranes were incubated overnight with the anti-SHP antibody
in a dilution 1:1000. Detection was performed with the
horseradish peroxidase conjugated anti-rabbit antibody and West
Pico Chemiluminescence Substrate (Thermo Scientific, USA).
RT-PCR studies
Total RNA was extracted from the cells and from freshly frozen
human liver using TRI Reagent (Sigma-Aldrich, USA). Reverse-
transcriptase polymerase chain reaction (RT-PCR) was carried out
by SuperScriptII reverse transcriptase (Invitrogen, USA). Subse-
quently, 1 ml of the resulting cDNA solution was used to amplify
cDNA by SHP and GAPDH specific primers: 59-ATGAGCAC-
CAGCCAACCA-39 (SHP, forward primer), 59-GCTCCTCCAG-
CAGAATCT-39(SHP, reverse primer), 59- GGAGTCAACG-
GATTTGGTCG -39 (GAPDH, forward primer), 59- ACTCCT-
TGGAGGCCATGTG -39 (GAPDH, reverse primer). The PCR
reaction was conducted for 30 cycles, consisting of denaturation
step at 94uC for 30 s, annealing for 1 min at 48uC and extension
for 1 min at 72uC, with use of GoTag Green Master Mix
polymerase (Promega, USA). After reaction, PCR products were
subjected to agarose gel electrophoresis, stained with Sybr Safe
(Invitrogen, USA) and photographed under UV light.
Statistical analysis
To analyze the SHP and cyclin D1 immunoreactivities, 100
cells from each tumor were counted in 10 HPF (high power fields)
under 406 objective. Both, the presence and the intensity of
staining were included into analysis. Three-point scale was applied
to diversify the intensity of immunoreaction, from high (3 points),
through medium (2 points) to weak (1 point) value. The results
were categorized by assigning a total score (enumerated as a sum
of products of the medium percentage of immunopositive cells
multiplied with the intensity value) and subjected to Mann-
Whitney U- test. Statistical association between the SHP
expression and cyclin D1 and AFP levels were evaluated by the
non-parametric Spearman’s rank correlation test.
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